Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Vestn Oftalmol ; 138(3): 41-45, 2022.
Article in Russian | MEDLINE | ID: covidwho-1934754

ABSTRACT

PURPOSE: To evaluate the severity of hemodynamic changes in the ocular vessels of patients recovered from COVID-19. MATERIAL AND METHODS: The study included 44 patients (88 eyes) aged 28-60 years, among them 24 (54.5%) women and 20 (45.4%) men, with SARS-CoV-2 infection confirmed by PCR no more than 2 months prior to enrollment and with no ophthalmological complaints within 2 months before the disease, as well as 20 healthy volunteers (40 eyes). At the time of the study all patients had a negative PCR result for SARS-CoV-2. The patients were divided into 2 groups. The first group comprised 24 patients who did not take any anticoagulants during the treatment. The second group consisted of 20 patients who received anticoagulants (Rivaroxaban (Xarelto)) at a dosage of 10 mg per day for 1-1.5 months. The maximum systolic (Vs), end-diastolic (Vd) blood flow velocity, as well as resistance index (RI) in the ophthalmic artery (OA), central retinal artery (CRA) and short posterior ciliary arteries (SPCA) were measured in all study patients with the ultrasound imaging system VOLUSON E8 Expert («Kretz¼, USA). Additionally, the flowmetry method was used to assess the volumetric ocular blood flow (VOBF) on Ocular Blood Flow Analyzer system («Paradigm Medical Industries, Inc.¼, USA). RESULTS: In the first group, a decrease in Vs and Vd was noted amid a significant increase of RI in CRA and SPCA, as well as an increase of RI in OA compared with the age-normal values (p<0.05). In the second group, a decrease in Vs and Vd was noted amid a significant increase of RI in CRA, as well as a decrease in Vs in SPCA and an increase of RI in OA relative to the age-normal values (p<0.05). A decrease in VOBF was noted in the first group in comparison to the second group and the age norm (p<0.05). CONCLUSION: Blood flow velocity parameters in the ocular vessels are reduced in patients recovered from COVID-19 compared to the age-normal values. There was a significant decrease in volumetric ocular blood flow parameters in COVID-19 patients who did not take any anticoagulants compared to the age-normal values. Anticoagulants intake has a positive impact on hemodynamic characteristics in the ocular vessels and volumetric ocular blood flow in patients with COVID-19.


Subject(s)
COVID-19 , Retinal Artery , Anticoagulants , Blood Flow Velocity/physiology , Female , Hemodynamics , Humans , Male , Ophthalmic Artery/diagnostic imaging , Ophthalmic Artery/physiology , Regional Blood Flow/physiology , Retinal Artery/diagnostic imaging , SARS-CoV-2 , Ultrasonography, Doppler, Color
2.
BMJ Case Rep ; 14(7)2021 Jul 12.
Article in English | MEDLINE | ID: covidwho-1307884

ABSTRACT

A rare case of a hypoplastic internal carotid artery (ICA) terminating in the ophthalmic artery with multiple intracranial saccular aneurysms in the contralateral ICA, anterior communicating artery fenestration and triple A2 was identified. The aetiology and pathogenesis of ICA hypoplasia are subjected to certain hypotheses. Developing several collaterals to preserve the blood supply of the ipsilateral cerebral hemisphere could result in aneurysm formation due to flow overload on the contralateral vasculature, but it could also result in hemicranial hypoplasia, cerebral atrophy and deep watershed infarcts, as in our case.


Subject(s)
Intracranial Aneurysm , Ophthalmic Artery , Anterior Cerebral Artery , Carotid Artery, Internal/diagnostic imaging , Cerebral Angiography , Humans , Intracranial Aneurysm/diagnostic imaging , Intracranial Aneurysm/etiology , Ophthalmic Artery/diagnostic imaging
3.
J Stroke Cerebrovasc Dis ; 29(8): 104982, 2020 Aug.
Article in English | MEDLINE | ID: covidwho-343281

ABSTRACT

We report a case of ophthalmic artery occlusion (OAO) in a young patient with COVID-19 infection that was on therapeutic anticoagulation with apixaban for deep venous thrombosis (DVT). A 48-year-old man with obesity was hospitalized with a severe form of COVID-19 infection, complicated with acute respiratory failure, septic shock, dilated cardiomyopathy and fungemia. Despite treatment with prophylactic enoxaparin (initial D-Dimer 1.14 µg/ml FEU (normal < 0.05 µg/ml FEU), D-Dimer increased to above 20 µg/ml FEU and patient continued to spike high fevers. This prompted further investigations and upper and lower extremities DVTs were confirmed and managed with enoxaparin 1 mg/kg twice daily. D-dimer level decreased to 4.98 µg/ml FEU while on therapeutic anticoagulation. Three weeks later pending hospital discharge, the anticoagulation was switched to oral apixaban 10 mg twice daily. Patient developed acute severe right eye visual loss of no light perception and was diagnosed with incomplete OAO. D-Dimer was elevated at 2.13 µg/ml FEU. Stroke etiological work-up found no embolic sources, resolution of the dilated cardiomyopathy and negative antiphospholipid antibodies. Treatment was changed to enoxaparin and no thrombotic events were encountered to date. Ocular vascular complications have not yet been reported in COVID-19. Controversy exists on the best management algorithm for the hypercoagulable state associated to COVID-19 Either direct oral anticoagulants or low-molecular-weight-heparin are considered appropriate at discharge for patients with venous thromboembolism. The optimum regimen for ischemic stroke prevention and the significance of D-Dimer for anticoagulation monitoring in COVID-19 remain unclear.


Subject(s)
Arterial Occlusive Diseases/etiology , Coronavirus Infections/drug therapy , Factor Xa Inhibitors/administration & dosage , Ophthalmic Artery , Pneumonia, Viral/drug therapy , Pyrazoles/administration & dosage , Pyridones/administration & dosage , Venous Thrombosis/drug therapy , Arterial Occlusive Diseases/diagnostic imaging , Betacoronavirus/pathogenicity , COVID-19 , Coronavirus Infections/blood , Coronavirus Infections/diagnosis , Coronavirus Infections/virology , Drug Substitution , Enoxaparin/administration & dosage , Factor Xa Inhibitors/adverse effects , Host Microbial Interactions , Humans , Male , Middle Aged , Ophthalmic Artery/diagnostic imaging , Pandemics , Pneumonia, Viral/blood , Pneumonia, Viral/diagnosis , Pneumonia, Viral/virology , Pyrazoles/adverse effects , Pyridones/adverse effects , Risk Factors , SARS-CoV-2 , Treatment Outcome , Venous Thrombosis/blood , Venous Thrombosis/diagnosis , Venous Thrombosis/virology , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL